{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-191512","form_type":"8-K","ticker":"BBOT","cik":"0001869105","company_name":"BridgeBio Oncology Therapeutics, Inc.","filed_at":"2026-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.191468+00:00","generated_at":"2026-05-15T02:24:04.102564+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"BridgeBio Oncology enters consulting agreement with former CEO Eli Wallace; equity vesting continues for 12 months","bullets":["Dr. Wallace provides R&D advisory services for 12 months retroactive to April 21, 2026.","Compensation: continued vesting of outstanding equity awards subject to service through each vesting date.","Vested stock options exercisable up to 2 years after consulting termination or original expiry, whichever earlier.","Wallace also receives Tier 1 severance benefits under the Executive Severance Plan via Separation Agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-191512","json":"https://secwatch.observer/filing/0001193125-26-191512.json","markdown":"https://secwatch.observer/filing/0001193125-26-191512.md","text":"https://secwatch.observer/filing/0001193125-26-191512.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526191512/0001193125-26-191512-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526191512/d68319d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T02:24:04.102564+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1227edfa57","claim":"Pedro J. Beltran was appointed as Member of the Board of Directors at BridgeBio Oncology Therapeutics, Inc..","evidence_excerpt":"Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526191512/0001193125-26-191512-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Member of the Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"b4bf2504ba","claim":"Eli Wallace resigned as President and Chief Executive Officer at BridgeBio Oncology Therapeutics, Inc..","evidence_excerpt":"Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526191512/0001193125-26-191512-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"b7858f8029","claim":"Pedro J. Beltran was appointed as President and Chief Executive Officer at BridgeBio Oncology Therapeutics, Inc..","evidence_excerpt":"Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526191512/0001193125-26-191512-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"bbef4e356c","claim":"Eli Wallace resigned as Member of the Board of Directors at BridgeBio Oncology Therapeutics, Inc..","evidence_excerpt":"Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526191512/0001193125-26-191512-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Member of the Board of Directors"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}